AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 16:35:07 14/06/2024 BST 5-day change 1st Jan Change
12,510 GBX +0.95% Intraday chart for AstraZeneca PLC -0.37% +18.02%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
Tesla, Inc. : Musk moves a step closer to the $56 billion prize and the transfer of Tesla's headquarters to Texas Our Logo
AstraZeneca: Farxiga approved for diabetes as of age 10 CF
AstraZeneca's Type-2 Diabetes Drug Wins Pediatric Approval in US MT
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S. DJ
AstraZeneca Gets FDA Approval for Pediatric Type-2 Diabetes Control Drug MT
AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes AN
European Equities Close Lower in Monday Trading Following Far Right Gains in EU Elections MT
UK Stocks Join Europe Retreat Ahead of US Fed Rate Decision MT
ASTRAZENECA : Berenberg raises its price target CF
AstraZeneca shares outperform, Berenberg raises target CF
Berenberg Raises AstraZeneca PT, Maintains Buy Rating MT
AstraZeneca's Tagrisso Secures Priority Review in the US MT
Berenberg Raises Price Target on AstraZeneca to GBP150 From GBP130, Cites More Confidence in Longer-Term Outlook, Keeps Buy Rating MT
JPMorgan cuts Aviva but lifts M&G AN
Investors remain cautious as political instability takes over Europe Our Logo
AstraZeneca: priority review in the USA for Tagrisso CF
Astra's Tagrisso gets US priority review for lung cancer AN
FTSE called down amid political uncertainty in EU AN
AstraZeneca Wins US FDA's Priority Review Tag for Expanded Use of Lung Cancer Drug MT
ASTRAZENECA : Berenberg gives a Buy rating ZD
ASTRAZENECA : JP Morgan reiterates its Buy rating ZD
Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During Bio International Convention 2024 to Establish New Rare Diseases Centre of Excellence CI
HSBC Raises AstraZeneca PT, Keeps Buy Rating MT
ASTRAZENECA : Deutsche Bank remains Neutral ZD
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6 USD
Average target price
174.4 USD
Spread / Average Target
+9.95%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca: Strong Q1 raises hopes of a guidance upgrade
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW